Microwave Ablation Market to Reach $1,015.5 Million by 2035

Microwave ablation market was valued at $380.2 million in 2025 and is projected to reach $1,015.5 million by 2035, growing at a CAGR of 10.4% during the forecast period (2026-2035). The increasing burden of cancer remains the most critical driver supporting demand for microwave ablation systems, particularly in oncology applications. According to the American Cancer Society, approximately 230 thousand new lung cancer cases and 42 thousand new liver cancer cases were reported in 2023, indicating a substantial patient pool requiring localized treatment solutions. Liver and lung cancers are among the primary indications for microwave ablation, especially in cases where surgical resection is not feasible due to patient condition or tumor location. In addition, data from the International Agency for Research on Cancer indicates a continued rise in cancer incidence across major developing economies, reinforcing long-term procedural demand. The growing number of patients diagnosed at intermediate or advanced stages further increases reliance on non-surgical interventions such as thermal ablation. Microwave ablation offers targeted tumor destruction without the need for full surgical excision, making it suitable for a broader patient population. This expanding addressable base directly translates into higher utilization of ablation systems and consumables. As diagnosis rates improve through screening programs, the volume of treatable cases is expected to increase steadily.

Browse the full report description of “Microwave Ablation Market Size, Share & Trends Analysis Report by Procedure Type (Percutaneous Ablation, Laparoscopic Ablation, and Open Surgical Ablation), by Application (Oncology, Cardiology, Gynecology, and Others), by End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), and Cancer Research Institutes), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/microwave-ablation-market

From a clinical perspective, microwave ablation is gaining preference due to its ability to achieve high technical success rates and effective tumor control, particularly in small to medium-sized lesions. Clinical studies report technical success rates exceeding 95% in liver tumor treatments, indicating strong reliability in real-world settings. Additionally, treatment success rates for small tumors have been reported above 85%, supporting its role as a viable alternative to conventional surgical approaches. The procedure’s capability to generate higher intratumoral temperatures and larger ablation zones enhances treatment efficiency, especially in complex tumor environments. Increasing clinical evidence supporting safety, reduced complication rates, and shorter recovery periods is encouraging wider adoption among physicians. This shift toward minimally invasive oncology interventions is reinforcing procurement decisions across hospitals and specialty centers. As a result, the growing clinical validation and expanding patient eligibility are expected to remain central to market growth over the forecast period.

Innovation Leaders Transforming the Microwave Ablation Market

The key players in the microwave ablation market include Medtronic Plc, Johnson & Johnson (Ethicon, Inc.), Boston Scientific Corporation, AngioDynamics, Inc, Terumo Corporation, among others. These companies are advancing innovation in microwave ablation systems through the development of high-precision energy delivery platforms, enhanced antenna designs, and real-time temperature monitoring technologies, enabling effective and controlled tumor destruction while improving procedural accuracy and patient outcomes, thereby supporting the growing demand for minimally invasive oncology treatments across clinical settings.

• In February 2026, Quantum Surgical announced the acquisition of NeuWave Medical, Inc., a medical device company whose products are used by physicians in over 70% of the top cancer centers in the United States. This acquisition supports Quantum Surgical’s strategy to democratize robotic-assisted tumor ablation treatments to reduce cancer mortality.
• In October 2025, Techsomed Ltd announced a pilot collaboration with Medtronic. The collaboration will combine Techsomed’s BioTraceIO360 software and Medtronic’s Emprint microwave ablation system for image-guided ablation therapy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Procedure Type
  • By Application
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Medtronic Plc, Johnson & Johnson (Ethicon, Inc.), Boston Scientific Corporation, AngioDynamics, Inc, Terumo Corporation, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Microwave Ablation Market Report Segment

By Procedure Type

• Percutaneous Ablation
• Laparoscopic Ablation
• Open Surgical Ablation

By Application

• Oncology
• Cardiology
• Gynecology
• Others

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Cancer Research Institutes

Global Microwave Ablation Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/microwave-ablation-market